The new study tests Seaside Therapeutics ‘ novel compound which selectively targets and potent on synaptic defect. Thomas R. Director of the National Institute of Mental Health, said: This project is the result of years of basic research, first identifying the genetic mutation and later deciphering the biochemical consequences of this mutation now. With the start of this first clinical study, we move one step closer to understanding how can this new candidate to in improving the in improving the quality of life of people with Fragile X Syndrome.
Clinical tests begin on Medication For Fragile X remedialNIH – supported scientists Seaside Therapeutics in Cambridge, Mass., a clinical trial of a potential medication begin designed to be a central neurochemical defect underlying Fragile X syndrome is the most frequent correct inherited cause of mental disability. It needs no medication the disturbance of the disturbance of neurological abnormalities date. The study will evaluate the safety, tolerability and optimal dosing in healthy volunteers.Swine Influenza is a respiratory disease of pigs of type A influenza that several outbreaks of outbreaks of influenza in pigs. Humanity virus can be spread from pigs to humans by contact with live pigs, and cases of human – to-human spread of swine flu viruses were document.